Home / Business and Economy / Sun Pharma Beats Revenue Expectations
Sun Pharma Beats Revenue Expectations
30 Oct
Summary
- Sun Pharma's Q2 revenue exceeded analyst projections.
- EBITDA margins surpassed market expectations.
- US market sales matched forecasts, driven by innovation.
India's largest pharmaceutical company, Sun Pharma Ltd., reported its September quarter financial results on October 30, 2026. The company's revenue for the quarter was ₹16,198.7 crore, exceeding the projected ₹15,766.1 crore and marking a 12% year-on-year increase.
Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) stood at ₹4,743 crore, surpassing the street's estimate of ₹4,403 crore. While EBITDA margins saw a slight decrease to 29.3% compared to 31.3% in the same quarter last year, they outperformed analyst expectations of 27.9%.
The US market, a key revenue driver, reported sales of $455 million, matching forecasts. This performance was supported by positive trends within the innovative medicines segment.
Following the announcement of these results, Sun Pharma's shares experienced a positive upturn, trading 2.2% higher at ₹1,800.
